Clinical trial
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating…
NCT04892472 · NovoCure GmbH, Industry · Terminated
Key facts
| NCT number | NCT04892472 |
|---|---|
| Title | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer |
| Official title | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer |
| Acronym | KEYNOTE B36 |
| Lead sponsor | NovoCure GmbH, Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Device, Drug |
| Interventions | NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg |
| Enrollment | 15 |
| Start date | Jul 12, 2021 |
| Primary completion | Jan 10, 2025 |
| Completion | Jan 10, 2025 |
| First posted | May 19, 2021 |
| Last update posted | Apr 23, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: